Skip to content
HowShorted

LIGAND PHARMACEUTICALS INC short interest in 2022

In 2022, LIGAND PHARMACEUTICALS INC's disclosed short interest ran from 9.22% of shares outstanding on 14 Jan 2022 to 4.69% on 30 Dec 2022, a change of -4.53 percentage points. The year's high was 9.22% on 14 Jan 2022 and its low 4.36% on 31 Oct 2022, averaging 5.81% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.58 days on 14 Jan 2022. Full history: LIGAND PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for LIGAND PHARMACEUTICALS INC in 2022

2022 in figures

Start of year
9.22% (14 Jan 2022)
End of year
4.69% (30 Dec 2022)
Change
-4.53 pp
High
9.22% (14 Jan 2022)
Low
4.36% (31 Oct 2022)
Average
5.81%
Highest days to cover
10.58 (14 Jan 2022)
SEC filings marked
8

Every report in 2022

LIGAND PHARMACEUTICALS INC short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20229.22%10.58
31 Jan 20228.18%7.66
15 Feb 20227.35%9.48
28 Feb 20227.31%5.29results (8-K), 10-K filed
15 Mar 20227.11%6.93
31 Mar 20227.32%8.83
14 Apr 20226.62%6.98
29 Apr 20226.62%8.26
13 May 20226.03%5.40results (8-K), 10-Q filed
31 May 20225.42%6.77
15 Jun 20225.38%8.41
30 Jun 20225.37%4.26
15 Jul 20225.18%7.46
29 Jul 20225.14%9.39
15 Aug 20224.97%8.13results (8-K), 10-Q filed
31 Aug 20224.79%7.96
15 Sep 20224.93%6.81
30 Sep 20224.68%4.46
14 Oct 20224.37%6.66
31 Oct 20224.36%5.30
15 Nov 20224.64%3.17results (8-K), 10-Q filed
30 Nov 20224.54%5.03
15 Dec 20225.13%3.75
30 Dec 20224.69%2.60

See also: LIGAND PHARMACEUTICALS INC's full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.